Ekso Bionics reports record Q2 sales of $5.0M; net loss narrows to $0.13 per share

EKSO BIONICS HOLDINGS, INC.

2024-Q2 EPS reported -$0.33 revenue$8,706,000

Revenue $5.0M up 5% YoY; gross margin improved to 53% from 48%.
Net loss $2.4M ($0.13/sh) vs $4.2M ($0.31/sh) in Q2 2023, narrowing significantly.
Sold 37 EksoHealth devices in Q2; initial Medicare claims for Ekso Indego Personal pending.
Operating expenses decreased across all categories: SG&A down 21%, R&D down 20%, G&A down 28%.
Cash at June 30, 2024 $5.9M, down from $8.6M at Dec 31, 2023.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.